Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2007 1
2009 1
2011 1
2012 1
2013 1
2014 2
2015 2
2016 1
2017 3
2019 2
2021 2
2022 2
2023 3
2024 4
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for kiyota cc
Search for Liyoka CC instead (1 results)
Incidence and risk factors associated with the development of hypothyroidism after postoperative chemoradiotherapy for head and neck cancer patients with high-risk features: Supplementary analysis of JCOG1008.
Shimizu H, Kodaira T, Kiyota N, Hayashi R, Nishino H, Asada Y, Mitani H, Hirayama Y, Onozawa Y, Nishio N, Hanai N, Ohkoshi A, Hara H, Monden N, Nagaoka M, Minami S, Fujii T, Tanaka K, Homma A, Yoshimoto S, Oridate N, Omori K, Ueda T, Okami K, Uemura H, Shiga K, Nakahira M, Asakage T, Saito Y, Sasaki K, Kitabayashi R, Ishikura S, Nishimura Y, Tahara M. Shimizu H, et al. Oral Oncol. 2024 Oct;157:106976. doi: 10.1016/j.oraloncology.2024.106976. Epub 2024 Aug 6. Oral Oncol. 2024. PMID: 39111143
Detection of long and short double-stranded RNAs.
Fukuhara T, Urayama S, Okada R, Kiyota E, Moriyama H. Fukuhara T, et al. Methods Mol Biol. 2011;744:129-44. doi: 10.1007/978-1-61779-123-9_9. Methods Mol Biol. 2011. PMID: 21533690
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer.
Funakoshi Y, Yakushijin K, Ohji G, Hojo W, Sakai H, Takai R, Nose T, Ohata S, Nagatani Y, Koyama T, Kitao A, Nishimura M, Imamura Y, Kiyota N, Harada K, Tanaka Y, Mori Y, Minami H. Funakoshi Y, et al. J Infect Chemother. 2022 Apr;28(4):516-520. doi: 10.1016/j.jiac.2021.12.021. Epub 2021 Dec 30. J Infect Chemother. 2022. PMID: 35090826 Free PMC article.

RESULTS: Anti-S1 antibody levels were significantly lower in the ICI and CC groups than in the HV group after the second dose (median optimal density: 0.241 [0.063-1.205] and 0.161 [0.07-0.857] vs 0.644 [0.259-1.498], p = 0.0024 and p < 0.0001, respectively). ...CONCLUS

…
RESULTS: Anti-S1 antibody levels were significantly lower in the ICI and CC groups than in the HV group after the second dose (median …
Presenilin-1 familial Alzheimer's disease mutation alters hippocampal neurogenesis and memory function in CCL2 null mice.
Kiyota T, Morrison CM, Tu G, Dyavarshetty B, Weir RA, Zhang G, Xiong H, Gendelman HE. Kiyota T, et al. Brain Behav Immun. 2015 Oct;49:311-21. doi: 10.1016/j.bbi.2015.06.014. Epub 2015 Jun 22. Brain Behav Immun. 2015. PMID: 26112421 Free PMC article.
To this end, we generated a mouse overexpressing familial AD (FAD) mutant human presenilin-1 (PS1) crossed with a knockout (KO) of the CC-chemokine ligand 2 (CCL2) gene. The PS1/CCL2KO mice developed robust age-dependent deficits in hippocampal neurogenesis associated with …
To this end, we generated a mouse overexpressing familial AD (FAD) mutant human presenilin-1 (PS1) crossed with a knockout (KO) of the CC …
Blowing time ratio and high-resolution manometry to evaluate swallowing function of patients with oral and oropharyngeal cancer.
Komatsu H, Furukawa T, Iritani K, Tatehara S, Takahashi M, Iwaki S, Kakei Y, Hasegawa T, Teshima M, Shinomiya H, Otsuki N, Hashikawa K, Kiyota N, Sasaki R, Akashi M, Nibu KI. Komatsu H, et al. Auris Nasus Larynx. 2022 Jun;49(3):477-483. doi: 10.1016/j.anl.2021.10.013. Epub 2021 Nov 14. Auris Nasus Larynx. 2022. PMID: 34789391
RESULTS: The blowing time ratio was significantly correlated with the swallowing pressures of the oropharynx (CC = 0.815, p = 0.004) and the velopharynx (CC = 0.657, p = 0.039), but not of the UES. ...
RESULTS: The blowing time ratio was significantly correlated with the swallowing pressures of the oropharynx (CC = 0.815, p = 0.004) …
Novel approach of prophylactic radiation to reduce toxicities comparing 2-step40 with 56-Gy simultaneous integrated boost intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the head and neck, an intergroup phase III trial (JCOG1912, NEW BRIDGE).
Yokota T, Zenda S, Kodaira T, Kiyota N, Fujimoto Y, Wasano K, Takahashi R, Mizowaki T, Homma A, Sasaki K, Machida R, Sekino Y, Fukuda H; Japan Clinical Oncology Group Radiation Therapy Study Group; Japan Clinical Oncology Group Head and Neck Cancer Study Group. Yokota T, et al. BMC Cancer. 2023 Nov 6;23(1):1068. doi: 10.1186/s12885-023-11503-z. BMC Cancer. 2023. PMID: 37932681 Free PMC article. Clinical Trial.
A Multicenter Retrospective Study of Mogamulizumab Efficacy in Adult T-Cell Leukemia/Lymphoma.
Iyama S, Sato T, Ohnishi H, Kanisawa Y, Ohta S, Kondo T, Mori A, Tsutsumi Y, Kuroda H, Kakinoki Y, Yamamoto S, Takahashi T, Shindo M, Torimoto Y, Sato K, Iwasaki H, Haseyama Y, Kohda K, Nagamachi Y, Hirayama Y, Sakai H, Hirata Y, Fukuhara T, Ikeda H, Kobune M, Kato J, Kurosawa M. Iyama S, et al. Clin Lymphoma Myeloma Leuk. 2017 Jan;17(1):23-30.e2. doi: 10.1016/j.clml.2016.09.009. Epub 2016 Sep 17. Clin Lymphoma Myeloma Leuk. 2017. PMID: 27727135
A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141.
Kiyota N, Hasegawa Y, Takahashi S, Yokota T, Yen CJ, Iwae S, Shimizu Y, Hong RL, Goto M, Kang JH, Sum Kenneth Li W, Ferris RL, Gillison M, Namba Y, Monga M, Lynch M, Tahara M. Kiyota N, et al. Oral Oncol. 2017 Oct;73:138-146. doi: 10.1016/j.oraloncology.2017.07.023. Epub 2017 Sep 1. Oral Oncol. 2017. PMID: 28939066 Free article. Clinical Trial.
23 results